87014-28-6

Upstream product

• 577-19-5 2-nitrophenyl bromide 
• 420-87-1 sodium 2,2,2-trifluoroethanolate 
• 609-73-4 o-nitroiodobenzene 
• 88-73-3 2-Chloronitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 528-29-0 1,2-Dinitrobenzene 
• 433-06-7 2,2,2-Trifluoroethyl p-toluenesulfonate 
• 88-75-5 2-hydroxynitrobenzene 
• 75-89-8 2,2,2-trifluoroethanol 

Downstream Products

• 57946-60-8 2-(2',2',2'-trifluoroethoxy)aniline 
• 62149-83-1 2-(2,2,2-trifluoroethoxy)aniline hydrochloride 
• 917514-08-0 4-heptafluoroisopropyl-2-(2,2,2-trifluoroethoxy)aniline 
• 178671-99-3 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 
• 1027544-70-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid ethyl ester 
• 1025909-31-2 8-Chloro-4-(3-{4-[2-(2,2,2-trifluoro-ethoxy)-phenyl]-piperazin-1-yl}-propylamino)-quinoline-3-carboxylic acid 
• 334930-12-0 1-[2-(2,2,2-trifluoroethoxy)-phenyl]-4-[3-(N-phthalimido)-propyl]-piperazine 
• 334930-13-1 1-(3-Aminopropyl)-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine 

Relevant academic research and scientific papers

BrettPhos ligand supported palladium-catalyzed C-O bond formation through an electronic pathway of reductive elimination: Fluoroalkoxylation of activated aryl halides

We report an unprecedented BrettPhos ligand supported Pd-catalyzed C-O bond-forming reaction of activated aryl halides with primary fluoroalkyl alcohols. We demonstrate that the Phosphine ligand (BrettPhos) possesses the property of altering the mechanistic pathway of reductive elimination from nucleophile to nucleophile. The Pd/BrettPhos catalyst system facilitates the reductive elimination of the oxygen nucleophile through an electronic pathway.

AMIDE DERIVATIVE, PESTICIDE CONTAINING SUCH COMPOUND AND USE THEREOF

Disclosed are a compound represented by the general formula (1) below which exhibits a high insecticidal effect, and a pesticide containing such a compound as an active ingredient. (1) (In the formula, A1, A2, A3 and A4 respectively represent a carbon atom or the like; R1 and R2 respectively represent a hydrogen atom, an alkyl group or the like; G1 and G2 respectively represent an oxygen atom or the like; X represents a hydrogen atom, a halogen atom or the like; n represents an integer of 0-4; Q1 represents a substituted phenyl group, a substituted heterocyclic group or the like; and Q2 represents a phenyl group having a haloalkylthio group or the like, a heterocyclic group or the like.)

PYRROLO 3,2-c]QUINOLINE DERIVATIVES CONTAINING HALOALKOXY GROUP AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

Pyrrolo [3,2-c] quinoline derivatives containing haloalkoxy group and pharmaceutically acceptable salts thereof

The present invention relates to a novel pyrrolo[3,2-c]quinoline derivatives containing haloalkoxy group, represented by Formula I, their pharmaceutically acceptable salts; process for preparation thereof; and pharmaceutical composition thereof for treati

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.

Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them

Indole derivatives characterized by having a 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid nucleus bearing a substituent in position 1,5, 6, 7 and 8. The derivatives are useful anti-inflammatory and analgesic agents and methods for their preparation

Aromatic Fluoroalkoxylation via Direct Aromatic Nucleophilic Substitution

The reaction of activated aryl and heteroaryl halides with fluorinated alkoxide anions is described.In all cases, substitution of the halogen by a fluoroalkoxy group was observed.The effect of solvent, time, temperature, the activating group, leaving group, and the nucleophile on this reaction is also discussed.